Search

The article "Canakinumab: Various toxicities: 2 case reports" from Reactions Weekly discusses two cases of patients who developed toxicities while being treated with canakinumab for TRAPS or HIDS. The patients experienced symptoms such as decreased appetite, nausea, malaise, and hyperbilirubinemia. One patient discontinued treatment and saw resolution of symptoms, while the other patient reported resolution of hyperbilirubinemia. The study highlights the importance of monitoring and managing potential toxicities associated with canakinumab therapy. [Extracted from the article]

This article discusses five case reports of patients with cystic fibrosis who developed hyperbilirubinemia while being treated with elexacaftor/ivacaftor/tezacaftor. The patients ranged in age from 16 to 44 years and all had Gilbert's syndrome. The onset of hyperbilirubinemia occurred at different times after starting the treatment, and in some cases, the dose of the medication was reduced to manage the condition. The article provides detailed information about each case, including the patients' bilirubin levels and the outcomes of the treatment adjustments. [Extracted from the article]

In a retrospective study of seven patients conducted between December 2020 and June 2023, it was found that patients who received off-label prophylactic treatment with glecaprevir/pibrentasvir for hepatitis C (HCV) infection developed hyperbilirubinemia. These patients were scheduled for cardiothoracic transplants and were receiving organs from HCV viraemic donors. Two of the patients developed hyperbilirubinemia as a result of the treatment, but one patient's viral load became undetectable and their hyperbilirubinemia resolved. Unfortunately, another patient experienced bradycardic arrest and died a few days after a heart transplant. [Extracted from the article]

A prospective study of 50 patients found that two patients developed veno-occlusive disease (VOD) of the liver or hyperbilirubinemia during treatment with inotuzumab-ozogamicin for B-cell acute lymphoblastic leukemia (ALL). One patient had previously undergone stem cell transplantation and developed grade 3 VOD of the liver, while the other patient developed ≥ grade 3 hyperbilirubinemia. The study did not provide specific information about the ages, sexes, dosages, or outcomes of the patients. [Extracted from the article]

This article reports on two cases of children with neuroblastoma who developed indirect hyperbilirubinemia during treatment with eltrombopag as engraftment failure prophylaxis. One child also exhibited lack of efficacy with busulfan, melphalan, and ursodeoxycholic acid. In both cases, the discontinuation of eltrombopag resulted in a decrease in bilirubin levels and a return to normal. These findings highlight the potential side effects and lack of efficacy of certain drugs in the treatment of neuroblastoma. [Extracted from the article]

A 63-year-old man experienced indirect hyperbilirubinemia after intentionally overdosing on naproxen in a suicide attempt. He presented to the emergency department with symptoms of nausea and abdominal pain, along with a history of depression and substance use disorder. Laboratory tests confirmed elevated levels of bilirubin, and other potential causes were ruled out. The hyperbilirubinemia was attributed to a metabolite of naproxen. The patient received treatment and his symptoms resolved the following day. [Extracted from the article]

It was considered that the worsening of pre-existing hyperbilirubinaemia was secondary to ceftriaxone. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 23-year-old man developed worsening of pre-existing hyperbilirubinaemia during treatment with ceftriaxone for leptospirosis [ I dosage and duration of treatment to reaction onset not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective study of 55 patients with advanced breast cancer, who were treated with palbociclib at breast department of Henan Cancer Hospital from September 2018 to September 2020, one woman [ I exact age not stated i ] was described, who developed hyperbilirubinaemia during treatment with palbociclib for advanced breast cancer. As a result, improvement in grade 3 hyperbilirubinaemia was observed. During the course of the treatment, she developed grade 3 hyperbilirubinaemia secondary to palbociclib therapy [ I time to reaction onset not stated i ]. [Extracted from the article]

Thoracic aorta graft infection by avibactam-resistant KPC-producing K. pneumoniae treated with meropenem/vaborbactam: a case report and literature review. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 71-year-old man developed hyperbilirubinaemia during treatment with tigecycline for I Klebsiella pneumoniae i infection. Additionally, evaluation of a new vascular surgery established the diagnosis of vascular graft/endograft infections. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 76-year-old man developed mild hyperbilirubinaemia during antibiotic therapy with amoxicillin/clavulanic acid. Amoxicillin/Clavulanic Acid Induced Hyperbilirubinemia in a Patient with Melanoma: A Rare Case Report. Since his admission, he had been receiving amoxicillin/clavulanic acid [amoxicillin/clavulanate; I route and dosage not stated i ]. [Extracted from the article]

So far, the Gilbert's syndrome was asymptomatic and no hyperbilirubinaemia was identified before the treatment with lenalidomide. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An adult man I [exact age not stated i ] developed hyperbilirubinaemia following unmasking of Gilbert syndrome during treatment with lenalidomide for multiple myeloma [ I route not stated i ]. Slow increase of bilirubin concentration during administration of lenalidomide, bortezomib and dexamethasone for multiple myeloma (unmasking previously undiagnosed Gilbert syndrome) and disappearance of necrobiotic xanthogranuloma after complete remission of multiple myeloma. [Extracted from the article]

She received potassium sodium hydrogen citrate as alkalinising treatment at the age of 3 years. Her bleeding frequency reduced after initiation of alkalinising treatment and number of hospitalisations because of massive bleeding was also decreased. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 3-year-old girl exhibited lack of efficacy during treatment with furosemide for alkaluria. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 65-year-old woman developed hyperbilirubinaemia and thrombocytopenia during off-label therapy with capecitabine for advanced metastatic hepatocellular carcinoma associated with Child-Pugh class B cirrhosis. However, she developed grade 3 hyperbilirubinaemia and thrombocytopenia secondary to capecitabine [ I time to reactions onsets not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 19-year-old woman developed recurrent, isolated indirect hyperbilirubinaemia and experienced unmasking of Gilbert syndrome during treatment with cytarabine for acute myeloid leukaemia [ I dosage and route not stated i ]. The findings indicated unmasking of Gilbert syndrome due to cytarabine therapy. [Extracted from the article]

Occurrence of hyperbilirubinemia in neonates given a short-term course of ceftriaxone versus cefotaxime for sepsis. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a single-center retrospective chart review of 88 neonates treated with cefotaxime or ceftriaxone for neonatal infections between 1 January 2013 and 31 August 2018, a neonate [ I sex and exact age at reaction onset not stated i ] was described, who developed hyperbilirubinaemia during empiric treatment with ceftriaxone for neonatal infection. After the initiation of ceftriaxone the normal baseline bilirubin level increased to an abnormal level consistent with hyperbilirubinaemia [ I duration of treatment to reaction onset and outcome not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective chart review of 24 adult patients with acute myeloid leukaemia who received gemtuzumab ozogamicin between 2004 and 2017, two adult patients [ I sexes not stated; exact ages not stated i ] were described, who showed hyperbilirubinaemia or increased AST during treatment with gemtuzumab ozogamicin for acute myeloid leukaemia [ I durations of treatments to reactions onsets and outcomes not stated i ]. An adult patient, who had acute myeloid leukaemia, started receiving gemtuzumab ozogamicin 3 mg/m SP 2 sp on day 1 [ I route not stated i ] along with idarubicin and cytarabine as induction therapy. An adult patient, who had acute myeloid leukaemia, started receiving gemtuzumab ozogamicin as a rescue therapy [ I route and dosage not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 33-year-old woman developed liver injury presenting as isolated direct hyperbilirubinaemia during treatment with cytarabine for acute myeloid leukaemia. RUCAM causality scale was suggestive of drug induced liver injury due to the use of cytarabine. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 57-year-old woman developed isolated conjugated hyperbilirubinaemia (ICH) following treatment with cytarabine for relapsed acute myeloid leukaemia. However, upon completion of cytarabine therapy, her total bilirubin (TBILI) and direct bilirubin (DBILI) were found to be elevated. Relapsed acute myeloid leukemia with isolated conjugated hyperbilirubinemia secondary to high-dose cytarabine therapy. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a study conducted between 2007 and 2019 involving 18 patients, a patient [age and sex not stated] was described who developed hyperbilirubinaemia during treatment with cytarabine and gemtuzumab ozogamicin for acute myeloid leukaemia [ I not dosages stated; routes and outcome not stated i ]. The patient had relapse of acute myeloid leukaemia after an allogeneic hematopoietic cell transplant. Gemtuzumab ozogamicin combined with intensive chemotherapy in acute myeloid leukemia patients relapsing after allogenic stem-cell transplantation. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a retrospective multicenter study involving 41 patients conducted between April 2018 and October 2018 in Japan, 2 patients were described who developed hyperbilirubinaemia (one patient) and died (one patient) during treatment with lenvatinib for advanced non-resectable hepatocellular carcinoma. However, one patient developed hyperbilirubinaemia requiring treatment discontinuation within 2 weeks of therapy initiation [ I outcome not stated i ]. The other patient died within 8 weeks of therapy initiation [ I immediate cause of death not stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a study involving 35 patients (aged 53-69 years) with metastatic neuroendocrine tumors and who were treated at a hospital in the USA, a patient [ I age and sex not stated i ] was described, who developed hyperbilirubinaemia during treatment with arginine, lutetium-(177lu)-oxodotreotide and lysine-hydrochloride [ I not all routes and dosages stated i ]. The patient, who had been diagnosed with metastatic neuroendocrine tumor, underwent PET/CT scan with Gallium-68-DOTATATE to identify receptor avidity. The patient received amino acid including arginine [arginine HCl] (2.5%) solution and lysine-hydrochloride [Lysine HCl] (2.5%) solution in 1 litre of sodium-chloride [normal saline] over 4 hours beginning 30 minutes prior to the radiotherapy treatment. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 72-year-old woman developed hyperbilirubinaemia and neutropenic fever during treatment with decitabine, and she also developed acute hepatotoxicity during treatment with cytarabine for acute myeloid leukaemia (AML). However, the course of decitabine therapy was complicated by hyperbilirubinaemia as well as neutropenic fever. Acute Hepatotoxicity After High-Dose Cytarabine for the Treatment of Relapsed Acute Myeloid Leukemia: A Case Report. [Extracted from the article]

A 46-year-old man developed hyperbilirubinaemia during empirical treatment with amphotericin-B liposomal. The man, who was diagnosed with acute myeloid leukaemia on hospitalisation, started receiving amphotericin-B liposomal 5 mg/kg daily [liposomal amphotericin-B; I route not stated i ] on hospital day 11 in addition to empiric treatment with meropenem, ciprofloxacin, vancomycin and aciclovir [acyclovir] for presistent high-grade fever. Isolated conjugated hyperbilirubinaemia was suspected secondary to amphotericin-B liposomal therapy. [Extracted from the article]

A study of 40 chronic hepatitis C patients, who were treated at four hospital in Australia between December 2016 and March 2018 under a special access scheme supported by Merck Sharp and Dohme Australia, described a patient, who developed hyperbilirubinaemia secondary to haemolysis during treatment with ribavirin for chronic hepatitis C [ I route and dose not stated i ]. Thereafter, the patient developed increased bilirubin levels (from 30 µmol/L to 50 µmol/L; hyperbilirubinaemia) and INR prolongation (from 1.3 to 1.5) [ I aetiology unknown i ] at treatment week 6. The patient's treatment was immediately (at treatment week 6) changed to sofosbuvir, velpatasvir and ribavirin due to initial concerns of protease inhibitor associated hepatotoxicity. [Extracted from the article]